152 related articles for article (PubMed ID: 31989369)
1. Salivary biomarkers in Alzheimer's disease.
Tvarijonaviciute A; Zamora C; Ceron JJ; Bravo-Cantero AF; Pardo-Marin L; Valverde S; Lopez-Jornet P
Clin Oral Investig; 2020 Oct; 24(10):3437-3444. PubMed ID: 31989369
[TBL] [Abstract][Full Text] [Related]
2. Salivary Aβ
Fan Z; Li Z; Zhao S; Chen Y; Su Y; Peng G; Luo B
J Neurol; 2023 Apr; 270(4):1945-1954. PubMed ID: 36562850
[TBL] [Abstract][Full Text] [Related]
3. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
4. No added diagnostic value of non-phosphorylated tau fraction (p-tau
Goossens J; Bjerke M; Struyfs H; Niemantsverdriet E; Somers C; Van den Bossche T; Van Mossevelde S; De Vil B; Sieben A; Martin JJ; Cras P; Goeman J; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
Alzheimers Res Ther; 2017 Jul; 9(1):49. PubMed ID: 28709448
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
6. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
8. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
9. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.
de Jong D; Jansen RW; Kremer BP; Verbeek MM
J Gerontol A Biol Sci Med Sci; 2006 Jul; 61(7):755-8. PubMed ID: 16870640
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis.
Struyfs H; Van Broeck B; Timmers M; Fransen E; Sleegers K; Van Broeckhoven C; De Deyn PP; Streffer JR; Mercken M; Engelborghs S
J Alzheimers Dis; 2015; 45(3):813-22. PubMed ID: 25633670
[TBL] [Abstract][Full Text] [Related]
13. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of selenium, redox status and their association with plasma amyloid/tau in Alzheimer's disease.
Krishnan S; Rani P
Biol Trace Elem Res; 2014 May; 158(2):158-65. PubMed ID: 24682919
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
[TBL] [Abstract][Full Text] [Related]
16. Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer's Disease Diagnosis.
Cui Y; Zhang H; Zhu J; Liao Z; Wang S; Liu W
Brain Sci; 2022 May; 12(5):. PubMed ID: 35624982
[TBL] [Abstract][Full Text] [Related]
17. Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease.
Pottiez G; Yang L; Stewart T; Song N; Aro P; Galasko DR; Quinn JF; Peskind ER; Shi M; Zhang J
J Proteome Res; 2017 Mar; 16(3):1228-1238. PubMed ID: 28112948
[TBL] [Abstract][Full Text] [Related]
18. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review on the Feasibility of Salivary Biomarkers for Alzheimer's Disease.
Bouftas M
J Prev Alzheimers Dis; 2021; 8(1):84-91. PubMed ID: 33336229
[TBL] [Abstract][Full Text] [Related]
20. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]